Not medical advice. Talk to your provider before using any peptide.
Full disclaimer
Alpha-MSH (α-Melanocyte-Stimulating Hormone)13 residues (approx.)SYSMEHFRWGKPVEach bubble = one amino acid. Size = residue mass. Color = chemical class.Uses closest standard amino acids for non-standard residues.Also known as: alpha-MSH, a-MSH, Ac-SYSMEHFRWGKPV-NH2
Over 6,500 PubMed papers back the melanocortin anti-inflammatory pathway, and two FDA-approved drugs already target it. Alpha-MSH (alpha-melanocyte-stimulating hormone) is the 13-amino-acid endogenous peptide that started it all, a POMC fragment that shuts down NF-kB signaling through MC1R activation on immune cells. The catch: a 20-minute plasma half-life makes native alpha-MSH impractical for direct clinical use. No human trial has ever tested the native form. Researchers studying melanocortin pharmacology still use it as a reference standard, but most people seeking anti-inflammatory benefits turn to KPV or synthetic analogs with better pharmacokinetics.
Thirteen amino acids. That's the full sequence of alpha-melanocyte-stimulating hormone (alpha-MSH, Ac-SYSMEHFRWGKPV-NH2, CAS 581-05-5), a neuropeptide cleaved from proopiomelanocortin (POMC) in the pituitary, hypothalamus, and immune cells. Alpha-MSH binds melanocortin receptors MC1R through MC5R. MC1R activation on macrophages and neutrophils blocks NF-kB nuclear translocation, cutting production of TNF-alpha, IL-1beta, IL-6, and IL-8. Catania's group mapped this pathway across 200+ references in a landmark review [1]. On melanocytes, the same MC1R signal drives melanin synthesis. In the hypothalamus, MC4R activation suppresses appetite through AgRP/NPY and POMC/CART circuits. Preclinical data is strong. Alpha-MSH reduced inflammation in animal models of colitis, arthritis, brain ischemia, organ transplant rejection, and fibrosis. The melanocortin pathway itself is clinically validated; setmelanotide (Imcivree) won FDA approval for MC4R-related obesity, and afamelanotide (Scenesse) is approved for erythropoietic protoporphyria. The limitation is pharmacokinetic. Native alpha-MSH degrades in roughly 20 minutes, with plasma bioavailability around 60 to 70 percent subcutaneously. Zero human clinical trials exist for the native peptide. The community skipped it entirely, moving to KPV (the C-terminal tripeptide that retains anti-inflammatory activity without pigmentation effects) or Melanotan II for tanning. Alpha-MSH remains a research-grade reference compound, not a practical therapeutic.
Alpha-MSH signals through five melanocortin receptors (MC1R through MC5R), all G-protein coupled receptors linked to stimulatory G-alpha subunits. Receptor binding activates adenylyl cyclase, raises intracellular cyclic AMP, and turns on protein kinase A (PKA). The anti-inflammatory action centers on MC1R. When alpha-MSH binds MC1R on immune cells, it blocks NF-kB from translocating into the nucleus. NF-kB is the master switch for inflammatory gene transcription. Blocking it cuts production of TNF-alpha, IL-1beta, IL-6, IL-8, nitric oxide, and prostaglandins. At the same time, alpha-MSH pushes cells toward IL-10 secretion, an anti-inflammatory cytokine. Catania and colleagues documented these mechanisms across multiple inflammation models [2]. The immune effects go beyond cytokine suppression. Alpha-MSH inhibits neutrophil chemotaxis, reduces adhesion molecule expression (ICAM-1, VCAM-1) on endothelial cells, and suppresses T-cell proliferation. This hits inflammation at three levels: signaling, cell recruitment, and adaptive immune activation. On melanocytes, MC1R activation stimulates tyrosinase and melanin production via MITF transcription factor upregulation. That's the pigmentation pathway, the original function scientists characterized before the anti-inflammatory story emerged. MC4R in the hypothalamus suppresses appetite by modulating AgRP/NPY and POMC/CART neuronal circuits. Alpha-MSH also engages JAK/STAT pathway modulation, MAPK inhibition, and the cholinergic anti-inflammatory pathway. The breadth of downstream signaling explains both the therapeutic promise and the side effect profile.
Alpha-MSH is one of the best-characterized anti-inflammatory peptides in preclinical science. Over 6,500 PubMed papers document its effects across dozens of inflammatory models. The melanocortin pathway is validated by two FDA-approved drugs (afamelanotide and setmelanotide). However, no human clinical trial has ever tested native alpha-MSH: all human data comes from synthetic analogs with different pharmacokinetics. A 2026 review frames the melanocortin system as a neuroendocrine-immune interface with therapeutic potential far beyond current approvals, but native alpha-MSH's 20-minute half-life makes it impractical for direct clinical use.
Catania A. "Alpha-melanocyte-stimulating hormone in the modulation of host reactions" (PMID 20651044): seminal review covering MC1R-MC5R pharmacology, anti-inflammatory mechanisms, and preclinical disease model data across 200+ references
Zero human clinical trials on native alpha-MSH. All efficacy data is preclinical. The 20-minute half-life means animal study protocols (often using continuous infusion or IP injection) don't translate to practical human subcutaneous dosing. Approved analogs have fundamentally different PK profiles.
The community doesn't use native alpha-MSH. It's been entirely replaced by KPV for anti-inflammatory purposes and by Melanotan II for tanning. People interested in melanocortin anti-inflammatory effects go straight to KPV: it's cheaper, more stable, doesn't cause pigmentation changes, and can be taken orally. Alpha-MSH discussion on forums is almost exclusively academic.
Strong preclinical science but no community adoption of native alpha-MSH. The community validated the melanocortin anti-inflammatory pathway through KPV and MT2, but skipped native alpha-MSH entirely due to its impractical pharmacokinetics. Science and community agree on the mechanism: they just disagree on which molecule to use.
| Level | Dose / Injection | Frequency |
|---|---|---|
| Beginner | 100mcg | Daily |
| Moderate | 250mcg | Daily |
| Aggressive | 500mcg | Daily |
Alpha-MSH is not a community peptide. It's a research reference compound, and the practical realities reflect that. Most people looking for melanocortin anti-inflammatory effects should consider KPV first; it's cheaper, more stable, and doesn't cause pigmentation. Reconstitution math for a 1 mg vial: add 2 mL bacteriostatic water. That gives you 500 mcg/mL, or 5 mcg per unit on a 100-unit insulin syringe. A 100 mcg beginner dose is 20 units. A 250 mcg moderate dose is 50 units. For a 5 mg vial with 2 mL BAC water: 2,500 mcg/mL, or 25 mcg per unit. A 250 mcg dose is 10 units. A 500 mcg dose is 20 units. The 5 mg vial is better value if you're running a full 8-week protocol. Alpha-MSH degrades faster than most peptides after reconstitution. Keep it at 2 to 8 degrees Celsius and use within 14 days. Don't freeze and thaw repeatedly. If the solution goes cloudy, throw it out. Source from established research chemical suppliers (Sigma-Aldrich, Tocris, MedChemExpress), not grey-market peptide vendors. Expect to pay $80 to $250 per milligram for genuine research-grade product.
Due to potential for melanocortin receptor desensitization with prolonged use, cycling is recommended. Monitor for skin pigmentation changes. The short half-life means effects dissipate rapidly upon discontinuation. Adjust cycle length based on research objectives and observed responses.
Melanocortin receptors (particularly MC1R and MC4R) show desensitization with prolonged agonist exposure. Animal studies demonstrate tachyphylaxis to alpha-MSH effects with chronic dosing. The recommended 8 weeks on / 4 weeks off cycle allows receptor resensitization. Shorter cycles may be appropriate if pigmentation changes become unwanted: effects reverse faster than with longer-acting analogs like MT2.
Or use the universal Peptide Calculator for any peptide.
Expected: Reduction in inflammatory biomarkers in research models. Mild skin pigmentation changes likely. Appetite suppression possible. No human efficacy data exists for this protocol: outcomes extrapolated from preclinical models.
Monitor: Track CRP, IL-6, complete skin exam for pigmentation changes. Monitor weight and appetite. Baseline and week 4/8 labs recommended.
Draw 2 mL of bacteriostatic water into a syringe and inject it slowly down the inside wall of the vial. Don't spray directly onto the lyophilized powder.
Alpha-MSH typically reconstitutes within 2 to 3 minutes. Don't shake the vial.
For a 1 mg vial reconstituted with 2 mL: 20 units equals 100 mcg (beginner), 50 units equals 250 mcg (moderate). For a 5 mg vial reconstituted with 2 mL: 10 units equals 250 mcg, 20 units equals 500 mcg.
Pinch a fold of abdominal fat, insert the needle at a 45 to 90 degree angle, and inject slowly. Rotate sites with each injection.
The 20-minute half-life means effects are brief; some researchers split to morning and evening dosing (8 to 12 hours apart) at the 250 mcg per injection level for the advanced protocol.
Allow the solution to reach room temperature before injecting. Cold solution increases discomfort at the injection site.
Store reconstituted alpha-MSH at 2 to 8 degrees Celsius, protected from light. Discard after 14 days or if the solution becomes cloudy.
KPV is the C-terminal fragment of alpha-MSH. Stacking makes little sense: KPV retains the anti-inflammatory activity via PepT1 without needing melanocortin receptors. Most people should just use KPV instead.
Different anti-inflammatory mechanisms. Alpha-MSH handles NF-kB suppression, BPC-157 promotes angiogenesis and tissue repair. Complementary for gut healing in theory.
TB-500 promotes cell migration and tissue repair via actin regulation. Combined with alpha-MSH's immune modulation, covers inflammation + repair. No known interaction concerns.
Both are immunomodulatory but through different pathways. TA1 enhances Th1 responses while alpha-MSH shifts toward anti-inflammatory IL-10 production. Theoretical synergy for balanced immune modulation.
Both activate melanocortin receptors. MT2 is a more potent, longer-lasting agonist. Combining adds no benefit and increases risk of pigmentation, nausea, and cardiovascular side effects.
Do not combineAlpha-MSH has immunosuppressive effects (IL-10 induction, NF-kB inhibition). Adding to existing immunosuppression could compound infection risk.
Animal studies show alpha-MSH can cause hypotension and bradycardia at higher doses. Combining with cardiovascular medications may amplify these effects.
Pricing updated 2026-04-09
The most important safety concern with alpha-MSH is MC1R-driven melanocyte stimulation. Repeated dosing can cause skin darkening and hyperpigmentation. For anyone with a history of melanoma or atypical moles, this is a hard stop, not a theoretical risk. MC1R activation promotes melanocyte proliferation, and alpha-MSH is contraindicated in active or prior melanoma (Catania et al.)[1]. New or changing moles during use require immediate discontinuation and dermatologic evaluation. Human data for native alpha-MSH is effectively zero. Every safety data point comes from preclinical models or from approved analogs (afamelanotide, setmelanotide) with different pharmacokinetic profiles. That context matters for interpreting what follows. Appetite suppression occurs through MC4R activation in the hypothalamus. At the 250 to 500 mcg dosing range, reduced food intake is expected. Unintended weight loss exceeding 5 percent of body weight warrants stopping the protocol. Individuals with eating disorders should not use alpha-MSH. Nausea, flushing, and fatigue have been reported in research settings. These typically appear in the first week and tend to resolve. Injecting before bed can reduce the impact of transient nausea. If nausea persists past week one, cutting the dose by 50 percent is reasonable. Cardiovascular effects are possible at higher doses. Animal studies documented mild changes in heart rate and blood pressure. Combining alpha-MSH with beta-blockers or antihypertensives could amplify these effects; weekly blood pressure and heart rate monitoring is recommended for the first month. Injection site reactions (redness, minor swelling) are typical for subcutaneous peptides. Rotating injection sites reduces local irritation. The short 20-minute half-life is actually a safety feature here. Side effects clear quickly once dosing stops. Contrast that with Melanotan II, where pigmentation changes can persist for months. Pregnancy and breastfeeding: no safety data exists. Alpha-MSH is contraindicated during pregnancy and lactation. Severe hepatic impairment may alter peptide metabolism; liver function should be assessed before starting. Immunosuppressant users need caution. Alpha-MSH induces IL-10 and suppresses NF-kB, the same direction as cyclosporine and tacrolimus. Stacking immunosuppressive mechanisms increases infection risk. Stop use and consult a physician for: unwanted pigmentation, persistent nausea or appetite loss affecting nutrition, any new or changing moles, unintended weight loss over 5 percent, or signs of hypersensitivity reaction.
Verify Alpha-MSH (α-Melanocyte-Stimulating Hormone) dosing and safety with a second opinion
Alpha-MSH is a niche research peptide with minimal consumer demand. It's not produced at scale by grey-market vendors the way MT2, BPC-157, or KPV are. This means fewer suppliers, less competition on quality, and less community testing to catch bad batches. The 13-amino-acid sequence is also more complex (and expensive) to synthesize than KPV's 3 amino acids, increasing the chance of truncated or impure product.
| Test | When | Target |
|---|---|---|
| CRP (C-Reactive Protein) | Baseline, week 4, week 8 | <3.0 mg/L (normal) |
| IL-6 | Baseline and week 8 (if available) | <7 pg/mL |
| Complete skin exam | Baseline, week 4, week 8, and 4 weeks post-cycle | — |
| Body weight | Weekly | — |
| Blood pressure and heart rate | Weekly for the first month | — |
Primary inflammatory marker to track anti-inflammatory response
Alpha-MSH directly suppresses IL-6 production via NF-kB inhibition
MC1R activation promotes melanocyte activity. Monitor all moles and pigmented lesions for changes
MC4R-mediated appetite suppression can cause unintended weight loss at higher doses
Melanocortin agonists can affect cardiovascular parameters, especially at aggressive doses
Establishment of dosing tolerance; measurable reduction in inflammatory biomarkers (CRP, IL-6) in research models
Observable anti-inflammatory effects in target tissue; potential mild pigmentation changes noted
Peak anti-inflammatory efficacy; sustained suppression of NF-kB-driven cytokine production
Full immunomodulatory response established; assess endpoints and determine continuation or cycling off
Days 1 through 3: Each injection triggers rapid MC1R and MC4R activation, but proteolytic degradation limits the effect window to 30 to 60 minutes. Brief NF-kB suppression occurs per dose. Expect mild nausea, flushing, and short-lived appetite suppression that should clear within an hour or two. No community data exists for native alpha-MSH during this phase; KPV users (the closest comparison) typically report feeling nothing in the first few days. Weeks 1 through 2: In animal models, repeated dosing begins reducing inflammatory markers like CRP and IL-6. Melanin synthesis starts ramping up in melanocytes. KPV users sometimes report mild improvement in gut symptoms by the end of week two. Nausea usually resolves. Subtle skin tone changes may start appearing. Appetite effects tend to stabilize. Weeks 3 through 4: This is the anti-inflammatory window based on preclinical data. Animal models show peak cytokine suppression in colitis and arthritis by this point. KPV users describe reduced bloating, better stool consistency, and less joint stiffness, though results aren't dramatic for most people. Weeks 5 through 8: Continued anti-inflammatory effect, but some animal studies flag receptor desensitization with prolonged exposure. KPV users who respond tend to plateau around weeks four through six. Pigmentation changes from MC1R activation become more apparent with native alpha-MSH. Watch for tachyphylaxis (reduced response from receptor desensitization) as a signal to cycle off.
Rapid MC1R/MC4R activation with each injection, but effects last only 30-60 minutes due to proteolytic degradation. Brief NF-kB suppression per dose.
No community data for native alpha-MSH. KPV users report feeling nothing in the first few days.
In animal models, repeated dosing begins showing measurable reduction in inflammatory markers (CRP, IL-6). Melanin synthesis starts ramping up in melanocytes.
KPV users (closest proxy): some report mild improvement in gut symptoms by end of week 2. Most report no obvious changes yet.
Peak anti-inflammatory effect in animal models. Significant cytokine suppression documented in colitis and arthritis models by this point.
KPV users: clearer reports of reduced bloating, improved stool consistency, less joint stiffness. Still not dramatic for most.
Continued anti-inflammatory effect. Some animal studies show receptor desensitization with prolonged exposure, reducing efficacy.
KPV users: those who respond tend to plateau by week 4-6. Pigmentation from alpha-MSH analogs (MT2) is well-established by this point. No equivalent data for native alpha-MSH.
Source: Estimated ~20 minutes based on plasma clearance studies; Catania A et al., Pharmacol Rev 2004
Loading the interactive decay curve.
Alpha-MSH has no FDA approval in any formulation. The native 13-amino-acid peptide is classified as a research chemical, legal to purchase for laboratory and investigational use but not for human therapeutic administration. It is not available through compounding pharmacies. Two synthetic melanocortin agonists targeting the same receptor family hold FDA approvals: setmelanotide (Imcivree, approved 2020 for MC4R-pathway obesity) and afamelanotide (Scenesse, approved 2019 for erythropoietic protoporphyria). These are distinct molecules with different pharmacokinetics and are not substitutes for native alpha-MSH in research contexts. Alpha-MSH is not specifically listed on the WADA prohibited substance list, but melanocortin agonists may fall under the "peptide hormones" category (S2). Athletes should consult WADA guidance before use. Research-grade alpha-MSH is available from suppliers such as Sigma-Aldrich, Tocris, and MedChemExpress. Grey-market peptide vendors rarely stock the native form. This content is for educational and informational purposes only. It does not constitute medical advice, diagnosis, or treatment. Consult a qualified healthcare provider before using any peptide.
Peptide Schedule Research TeamReviewed Apr 20266 Citations
